• Jessica Barrett, Claire Broderick, Hannah Soulsby, Paul Wade, and William Newsholme.
• Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK jessica.barrett@gstt.nhs.uk.
• J. Antimicrob. Chemother. 2016 Jan 1; 71 (1): 220-5.

BackgroundStrongyloides stercoralis infection presents with varying degrees of severity, but it often primarily involves the small bowel. In severe infection and cases of hyperinfection, ileus and small-bowel obstruction may prevent enteral absorption of anthelminthics such as ivermectin. At present there are no parenteral anthelminthics licensed for use in humans.MethodsHere, we describe two cases of severe S. stercoralis infection treated with an unlicensed veterinary preparation of subcutaneous ivermectin, and we discuss the published reports of the use of this treatment elsewhere.ResultsBoth patients were successfully treated with subcutaneous ivermectin, and both recovered completely.ConclusionsDespite the limited published experience of parenteral ivermectin use, there is evidence that it may be a safe and effective treatment for severe strongyloidiasis. However, more data are needed to guide dosing schedules and monitoring for toxicity.© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

16 keywords...

hide…